Abstract
Chronic inflammatory demyelinating polyneuropathy with anti-myelin associated glycoprotein antibodies represents a small subgroup of patients for whom management may not be straightforward. A recent study offers insight into this issue, with results suggesting priority should be given to the clinical phenotype.
Original language | English |
---|---|
Pages (from-to) | 301-302 |
Journal | European Journal of Neurology |
Volume | 30 |
Issue number | 2 |
Early online date | 21 Nov 2022 |
DOIs | |
Publication status | Published - Feb 2023 |
Keywords
- Neurology (clinical)
- Neurology